<SEC-DOCUMENT>0001213900-17-008921.txt : 20170818
<SEC-HEADER>0001213900-17-008921.hdr.sgml : 20170818
<ACCEPTANCE-DATETIME>20170818160621
ACCESSION NUMBER:		0001213900-17-008921
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		4
CONFORMED PERIOD OF REPORT:	20170816
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20170818
DATE AS OF CHANGE:		20170818

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			NutriBand Inc.
		CENTRAL INDEX KEY:			0001676047
		STANDARD INDUSTRIAL CLASSIFICATION:	ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUPPLIES [3842]
		IRS NUMBER:				811118176
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			0131

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-55644
		FILM NUMBER:		171041185

	BUSINESS ADDRESS:	
		STREET 1:		309 CELTIC COURT
		CITY:			OVIEDO
		STATE:			FL
		ZIP:			32765
		BUSINESS PHONE:		385-881-3385

	MAIL ADDRESS:	
		STREET 1:		309 CELTIC COURT
		CITY:			OVIEDO
		STATE:			FL
		ZIP:			32765

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Nutriband Inc.
		DATE OF NAME CHANGE:	20160601
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>f8k081617_nutribandinc.htm
<DESCRIPTION>CURRENT REPORT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SECURITIES
AND EXCHANGE COMMISSION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Washington,
DC 20549</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>FORM
8-K</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CURRENT
REPORT </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to Section 13 or 15(d) of</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
Securities Exchange Act of 1934</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Date
of Report (Date of earliest event reported) August 16, 2017 </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Nutriband,
INC.</B></FONT></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 32%; font: 10pt Times New Roman, Times, Serif; padding-top: 0; padding-right: 0; border-bottom: Black 1.5pt solid; padding-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nevada</FONT></TD>
    <TD STYLE="width: 2%; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="width: 32%; font: 10pt Times New Roman, Times, Serif; padding-top: 0; padding-right: 0; border-bottom: Black 1.5pt solid; padding-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>000-55654</I></FONT></TD>
    <TD STYLE="width: 2%; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="width: 32%; font: 10pt Times New Roman, Times, Serif; padding-top: 0; padding-right: 0; border-bottom: Black 1.5pt solid; padding-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">81-1118176</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding: 0; text-align: center; font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(State
or Other Jurisdiction<BR>
of&nbsp;Incorporation)</FONT></P></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Commission
    File Number)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding: 0; text-align: center; font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(I.R.S.
Employer<BR>
Identification No.)</FONT></P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; width: 49%; padding-top: 0; padding-right: 0; border-bottom: Black 1.5pt solid; padding-left: 0; text-align: center; font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>309
Celtic Ct., Oviedo Florida </B></FONT></P></TD>
    <TD STYLE="width: 2%; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 49%; font: 10pt Times New Roman, Times, Serif; padding-top: 0; padding-right: 0; border-bottom: Black 1.5pt solid; padding-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>32765</B></FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Address
    of Principal Executive Offices)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Zip
    Code)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(800) 377-2137</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Registrant&rsquo;s
Telephone Number, Including Area Code</FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Former
name or former address, if changed since last report)</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see General Instruction A.2. below):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#9744;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#9744;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#9744;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#9744;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule&nbsp;405 of the Securities Act of 1933 (17 CFR &sect;230.405) or Rule&nbsp;12b-2 of the Securities Exchange
Act of 1934 (17 CFR &sect;240.12b-2).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Emerging growth company <FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">If an emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided
pursuant to Section&nbsp;13(a)&nbsp;of the Exchange Act. <FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Item
2.02 Results of Operations and Financial Condition</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 16, 2017, The Company has issued a Press Release announcing that it has received the third party testing report on the
patent valuation from Sinorica Valuation, a Washington DC based patent valuation firm. The valuation is based on Nutriband filing
for&nbsp;full USPTO Utility patents, which the company intends to file immediately following the analysis.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recently acquired Advanced Health Brands, a Michigan company. Following this, Advanced health Brands then became the Nutriband
Life Sciences division of the company which focuses mostly on transdermal prescription drugs and transdermal research.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">FOR
THE FULL TERMS OF THE Press Release, PLEASE REFER TO THE COPY THEREOF FILED AS EXHIBIT 99.2 TO THIS REPORT.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
company issued a Press Release on August 16, 2017.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
8.01 Other Events.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">DISCLOSURE
REGARDING FORWARD-LOOKING STATEMENTS</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Throughout
this report, we make statements that may be deemed &quot;forward-looking&quot; statements within the meaning of Section&nbsp;27A
of the Securities Act of 1933, as amended, and Section&nbsp;21E of the Securities Exchange Act of 1934, as amended. All statements,
other than statements of historical facts, that address activities, events, outcomes and other matters that Chancellor plans,
expects, intends, assumes, believes, budgets, predicts, forecasts, projects, estimates or anticipates (and other similar expressions)
will, should or may occur in the future are forward-looking statements. These forward-looking statements are based on management's
current belief, based on currently available information, as to the outcome and timing of future events. When considering forward-looking
statements, you should keep in mind the risk factors and other cautionary statements in this report.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
forward-looking statements that we may make are based on our current expectations and beliefs concerning future developments and
their potential effects on us. There can be no assurance that future developments affecting us will be those anticipated by us.
Any forward-looking statements are subject to the risks and uncertainties that could cause actual results of operations, financial
condition, cost reductions, acquisitions, dispositions, financing transactions, operations, expansion, consolidation and other
events to differ materially from those expressed or implied in such forward-looking statements. We undertake no obligation to
publicly update or revise any forward-looking statements. As a result, the reader is cautioned not to rely on these forward-looking
statements. Due to known and unknown risks, the company&rsquo;s actual results may differ materially from its expectations or
projections.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">While
most risks affect only future costs or revenues anticipated by the company, some risks may relate to accruals that have
already been reflected in results of operations. The company&rsquo;s failure to receive payments of accrued amounts or if
liabilities are incurred in excess of amounts previously recognized, a charge against future earnings could result. In
addition, any forward-looking statements should be considered in context with various disclosures made by us about our
business including, without limitation, the risk factors more particularly described below in &ldquo;Risk
Factors.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Item
9.01. Financial Statements and Exhibits. </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
Exhibits.</FONT></P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 9%; font: 10pt Times New Roman, Times, Serif; padding-top: 0; padding-right: 0; border-bottom: Black 1.5pt solid; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibit
    Number</FONT></TD>
    <TD STYLE="width: 1%; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="width: 90%; font: 10pt Times New Roman, Times, Serif; padding-top: 0; padding-right: 0; border-bottom: Black 1.5pt solid; padding-left: 0; text-indent: 0; text-align: left; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Description&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><A HREF="f8k081617ex99i_nutribandinc.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Press release issued by Nutriband, Inc. August 16, 2017</FONT></A></P></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0">99.2</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><A HREF="f8k081617ex99ii_nutribandinc.htm">Patent Valuation Summary</A></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SIGNATURES</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">PURSUANT
TO THE REQUIREMENTS OF THE SECURITIES EXCHANGE ACT OF 1934, THE REGISTRANT HAS DULY CAUSED THIS REPORT TO BE SIGNED ON ITS BEHALF
BY THE UNDERSIGNED THEREUNTO DULY AUTHORIZED.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Nutriband,
        INC.</B></FONT></P></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0; width: 60%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0; width: 4%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0; width: 36%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
    August 18, 2017</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0 0 1.5pt; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    Gareth Sheridan </FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">R:
    Gareth Sheridan</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>f8k081617ex99i_nutribandinc.htm
<DESCRIPTION>PRESS RELEASE ISSUED BY NUTRIBAND, INC. AUGUST 16, 2017
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0; text-align: right"><B>Exhibit 99.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><B>$120.7
MILLION INDEPENDENT VALUATION RECEIVED ON NUTRIBAND INC. PHARMACEUTICAL IP</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Oviedo,
Fla. &ndash; Aug 15, 2017 &ndash; Nutriband Inc. (OTC: NTRB) , a Nevada Corporation, is pleased to announce that it has received
an independent 3<SUP>rd</SUP> party Intellectual Property valuation of 120.7M USD on its 6 patent pending prescription drugs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
Jul 24, 2017, The Company received the third party testing report on the patent valuation from Sinorica Valuation, a Washington
DC based patent valuation firm.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
valuation is based on Nutriband filing for full USPTO Utility patents which the company intends to file immediately following
the analysis.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recently acquired Advanced health brands, a Michigan company. Following this, Advanced health Brands then became the Nutriband
Life Sciences division of the company which focuses mostly on prescription drugs and transdermal research.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nutriband
Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nutriband</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nutriband
is a unique, result&rsquo;s driven, health and pharmaceutical Company based in Orlando Florida.&nbsp; Unlike traditional health
product companies, Nutriband found its start by spotting and targeting a gross and virtually unexplored niche in the supplement
market through its method of ingredient delivery. All Nutriband products are based around the science of transdermal / Topical
technologies. From what started in only Supplements, Nutriband has now also developed an impressive platform to develop drugs
and diagnostics that treat diseases in many areas of medicine.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>www.nutriband.com</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sinorica
Valuation</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Sinorica
Valuation is a valuation firm helping clients determine and interpret the value of their patent(s), tangible assets, and intellectual
properties. Sinorica is located in the Washington, D.C. Metropolitan area, residence of the US Patent Office, allowing them access
to expansive search facilities and advancing their valuations research.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><U>www.sinoricavaluation.com</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">About
Our Forward-Looking Statements</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain
statements contained in this press release, including, without limitation, statements containing the words &ldquo;believes&rdquo;,
&ldquo;anticipates&rdquo;, &ldquo;expects&rdquo; and words of similar import, constitute &ldquo;forward-looking statements&rdquo;
within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve both known
and unknown risks and uncertainties. Our actual results may differ materially from those anticipated in our forward-looking statements
as a result of a number of factors, including our ability to create, sustain, manage or forecast our growth; our ability to attract
and retain key personnel; changes in our business strategy or development plans; competition; business disruptions; adverse publicity
and international, national and local general economic and market conditions. Except as required by applicable law, we undertake
no obligation to revise or update any of our forward-looking statements in order to reflect any event or circumstance that may
arise after the date hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
more information, contact:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gareth
Sheridan</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CEO</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nutriband
Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">407
880-6810</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>info@nutriband.com</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>www.nutriband.com</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>3
<FILENAME>f8k081617ex99ii_nutribandinc.htm
<DESCRIPTION>PATENT VALUATION SUMMARY
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0; text-align: right"><B>Exhibit 99.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48%; font-size: 10pt"><IMG SRC="ex99-2_001.jpg" ALT="">&nbsp;</TD>
    <TD STYLE="width: 52%; font-size: 10pt; text-align: right"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt"><B>Sinorica Valuation, LLC</B></FONT></P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt"><B>20251 Century Blvd., Suite 140</B></FONT></P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt"><B>Germantown, MD 20874</B></FONT></P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt"><B>(240) 788-3313</B></FONT></P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 12pt"><B>Patent
Valuation Summary</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">In analyzing the six following provisional patents,
our team considered factors including but not limited to: a market analysis, future cash flows, NPV calculation, likelihood of
patentability and approval. These factors were considered by our team of analysts to conclude the final estimate value of each
patent, listed below<B>:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 18pt; text-indent: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 18pt; text-indent: 0pt"><FONT STYLE="font-family: Symbol">&middot;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Patent Application 62/455,473: <B>$16.3 million</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 18pt; text-indent: 0pt"><FONT STYLE="font-family: Symbol">&middot;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Patent Application 62/455,476: <B>$42.8 million</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 18pt; text-indent: 0pt"><FONT STYLE="font-family: Symbol">&middot;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Patent Application 62/455,487: <B>$15.2 million</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 18pt; text-indent: 0pt"><FONT STYLE="font-family: Symbol">&middot;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Patent Application 62/455,500: <B>$17.7 million</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 18pt; text-indent: 0pt"><FONT STYLE="font-family: Symbol">&middot;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Patent Application 62/455,507: <B>$19 million</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 18pt; text-indent: 0pt"><FONT STYLE="font-family: Symbol">&middot;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Patent Application 62/455,509: <B>$9.6 million</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 14pt"><B>Total
Patent Portfolio Valuation: $120.7 million</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Disclaimer</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The reader or anyone who is relying on
this valuation analysis for any purpose is advised that the value outcome is absolutely subjective however based on the analyst's
experiences and suggestions. All information contained herein is for reference and discussion only and is drawn from a full and
complete valuation report. For full details and analysis, please reference the full report.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Further, this report has been conducted
based on the assumption that all patents referenced herein are successfully converted to full utility patents issued by the USPTO.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">SINORICA VALUATION, LLC AND THE SIGNED
ANALYST BEAR NO RESPONSIBILITIES TO GUARANTEE THE ACCURACY OF THE DATA NOR THE VALUE CONCLUDED IN FAVOR OR NOT IN FAVOR WHATSOEVER.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 72.5pt 0pt 273.6pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; padding-bottom: 1.5pt; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; padding-bottom: 1.5pt; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    Ming Chow</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 35%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">August
    17, 2017</FONT></TD>
    <TD STYLE="width: 30%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 35%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ming
    Chow</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certified Patent
    Valuation Analyst</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>ex99-2_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex99-2_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !4 +4# 2(  A$! Q$!_\0
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MNFPT[0XI-3^'GA;XFKJ5GJ#7\BC1['PWXNTX:C>ZG'IGV6]MM10Q/9V\5]<
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MC?WAOV3IM$\=ZO\ &7X?^,M.\*_&F]^(?B#75\77'AF[U'1M?^%WBW5-%O\
MQ!\'OB!X>L_$NCOXLT:-].NM7\(Z\-4TW5/!'C"XCU[1$_LV\\6>'/%FEX;\
M!_##QGX^_;*^'?B34+'QUI_Q=U?PI>_$#P/>Z<]E967A_4_@GX*^%MYH"ZC#
MJ<EQK)NK;P;-?W^H6,6DSZ%<:S::>-M[;17T_11PF*Q-/%5</AZU:E@:"Q.,
MJ4J<IPPN'E7HX:->O**:I4GB,10HJ<K)U*L(];K.=6G3E3C.I"$JTW3I1E))
MU*BA.HX03^*2ITYSLM>6,GTU^MT1(T6.-51$541$4*B(H"JJJH 55  50
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D !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
